In collaboration with Briya, a leading top 10 pharmaceutical company conducted a comprehensive study on metastatic non-small cell lung cancer (NSCLC) in patients exhibiting wild-type characteristics. The research aimed to determine the average time from both pathological and molecular diagnosis to the start of treatment, as well as assess the typical number of biopsies performed in this patient group. A key focus of the study was to explore the correlation between smoking and the progression of the disease, offering valuable insights into patient management and treatment outcomes.